Use our Whitepapers to Expand Your Knowledge
These top level issues are discussed in our White Papers, leveraging our industry expertise to help customers answer the most challenging preclinical research questions.
NAFLD/NASH drug development is hindered by a lack of preclinical models which capture all clinical aspects of this complex disease. Notably, there is a lack of models which combine the pathology and metabolic aspects of human NASH. Download our White Paper to discover a new, more translational model which better recapitulates the combined dysmetabolic and fibrosis NASH phenotype, to accelerate your NASH drug discovery programs.
The biggest challenge in modeling human diabetes in animal models is a lack of translatable platforms fully capturing all aspects of this progressive condition including polygenic disease, pre-diabetic state, and complications. New translational platforms are required that model multiple aspects of human disease, and can be used to develop agents that control more than one diabetes risk factor. Read our White Paper to learn about the development of highly translatable rodent and NHP models, more closely mirroring human disease development for more predictive preclinical study.
Exploring Translational Capabilities of PDX Models across In Vivo, In Vitro, and Ex Vivo Applications
While PDX have dramatically improved predictivity of in vivo oncology drug development studies, the model's nature and main use in immunodeficient mice has limited early stage and immuno-oncology drug discovery utilities. Read our White Paper to explore PDX-derived cell lines and 3D PDX screening panels for in vitro/ex vivo assays, as well as humanized PDX models for immunotherapy assessment, to understand how PDX model applications are now being expanded across the full preclinical research continuum.
With the continued rise of immunotherapeutics, more preclinical research is moving towards using immunocompentent models, which are required to assess immunomodulatory agents. Choosing the correct model from the variety available can be difficult, but is needed to help to efficiently progress novel agents. Download our White Paper to learn which human specific and mouse analogue models are available, and how to select the best model for any given immuno-oncology study.
How to Use CrownBio's Integrated Oncology Portfolio for Target Identification and Mechanism of Action Elucidation
Target identification and MOA studies are a vital early stage in cancer drug development, and require disease-relevant cell-based platforms, with linked later stage models to accelerate lead compounds. Discover how CrownBio’s integrated oncology portfolio of in vitro, in vivo, and ex vivo products and services help advance target identification and MOA studies within drug discovery programs, allowing go/no-go decisions to be made with confidence.
Human tumor bearing humanized mouse models are needed for the preclinical assessment of human-specific immunotherapeutics. Given the complexity of these models (including hCD34+ and hPBMC mice combined with PDX and traditional xenografts), the key to optimizing their use is to bring together an in depth knowledge of each model features and limitations, with bespoke study designs, centred around the specific question being asked in each study. Download our White Paper to discover different immune system humanization strategies and how these result in models with differing pros and cons, alongside successful model utilization in cancer pharmacology case studies.
Oncology drug development has an overly high attrition rate for novel agents in late-phase clinical trials, which needs to be improved to enhance the efficiency and cost-effectiveness of developing new therapies. Precision profiling using Patient-Derived Xenografts (PDX), the most predictive preclinical models available, allows the identification of molecular biomarkers and genetic signatures of response for patient stratification to improve response and reduce attrition rates. Let CrownBio’s Precision Profiling White Paper help you understand who will benefit from your treatment before you enter the clinic.
New approaches are needed in oncology, to better predict clinical efficacy within preclinical assessment. Mouse Clinical Trials (MCT) using patient-derived xenograft (PDX) models are a highly predictive alternative to traditional drug discovery methods, providing a more clinically relevant situation, a better perspective of patient-to-patient heterogeneity, and a framework for biomarker discovery. Download our White Paper to discover the various types of MCT, and identify which method will best progress any given drug development program.
Life Science Products
To accurately determine antibody drug effects in in vivo studies and immunoassays, negative control isotype antibodies are required. They provide an especially reliable method to effectively differentiate between specificity versus background in a range of drug development assays. Download our White Paper to learn why isotype controls are essential research tools, how to select the correct isotype control for your study, and why isotype controls should never be swapped for non-optimal control factors such as PBS.